scholarly journals MP687SUCCESSFUL COST EFFECTIVE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS USING LOW DOSE VALGANCICLOVIR

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i568-i568
Author(s):  
Osama Gheith ◽  
Torki Al Otaibi ◽  
Medhat A Halim ◽  
Hany Mansour ◽  
Hany Mansour ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Low Dose ◽  
Cost Effective ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cytomegalovirus Disease ◽  
Effective Prevention

scholarly journals FP865SUCCESSFUL COST EFFECTIVE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS USING LOW DOSE VALGANCICLOVIR

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii366-iii366
Author(s):  
Medhat Halim ◽  
Torki Alotaibi ◽  
Osama Gheith ◽  
Hany Adel ◽  
Ahmed Mosaad ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Low Dose ◽  
Cost Effective ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cytomegalovirus Disease ◽  
Effective Prevention

Short Course of Low Dose Valgancicolvir Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients.

2014 ◽  
Vol 98 ◽  
pp. 259-260
Author(s):  
B. Gopal ◽  
G. Sudhakar ◽  
A. Mohapatra ◽  
A. Abraham ◽  
A. Valson ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Low Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cytomegalovirus Disease ◽  
Short Course

scholarly journals MP689EFFICACY AND SAFETY OF LOW DOSE VERSUS HIGH DOSE VALGANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN INTERMEDIATE RISK KIDNEY TRANSPLANT RECIPIENTS

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i568-i569
Author(s):  
Medhat Abdel Halim ◽  
Torki Al-Otaibi ◽  
Osama Gheith ◽  
Hany Adel ◽  
Ahmed Mosaad ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Low Dose ◽  
High Dose ◽  
Intermediate Risk ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cytomegalovirus Disease

scholarly journals SaO030EFFICACY AND SAFETY OF LOW DOSE VERSUS FULL DOSE VALGANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii36-iii36
Author(s):  
Medhat Abdel Halim ◽  
Torki Al-Otaibi ◽  
Osama Gheith ◽  
Hany Adel ◽  
Ahmed Mosaad ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Low Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cytomegalovirus Disease ◽  
Full Dose

CONTROLLED TRIAL OF IL2R ANTIBODY BASILIXIMAB (SIMULECT) VS LOW DOSE OKT3 IN CADAVER KIDNEY TRANSPLANT RECIPIENTS.

2000 ◽  
Vol 69 (Supplement) ◽  
pp. S156 ◽  
Author(s):  
Hamid Shidban ◽  
M. Sabawi ◽  
S. Aswad ◽  
G. Chambers ◽  
I. Castillon ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Low Dose ◽  
Controlled Trial ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cadaver Kidney

SO056THE CLINICAL AND IMMUNOLOGICAL IMPACT OF LOW DOSE RITUXIMAB IN CLINICAL NEPHROLOGY

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Sunu Alex
Keyword(s):  
B Cells ◽  
B Cell ◽  
Low Dose ◽  
Cost Effective ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cell Percentage ◽  
Steroid Dependent ◽  
One Year

Abstract Background and Aims Currently, the dose of rituximab used in nephrology practice is mostly extrapolated from the dose used in lymphoproliferative disorders. It is possible that a lesser dose may suffice when treating a non-neoplastic disorder. We conducted this study to study the clinical response and CD19 B cell suppression with a single dose of 100mg rituximab in nephrology practice Method This was a single center prospective study of role of 100mg rituximab as initial dose in steroid dependent (SDNS), frequently relapsing nephrotic syndrome (FRNS), idiopathic membranous nephropathy (MN) and high immunologic risk kidney transplantation with subsequent doses based on CD19 B cell reconstitution. Results Following 100mg rituximab in 42 patients, CD19 B cell percentage decreased from 16.3+7.6 to 0.3±0.3, 1.9±1.7 and 4.0±4.5 by 30, 90 and 180 days respectively. At 30th day, 40(95.2%) had CD19 B cell count <1%. Of the 30 patients with SDNS and FRNS followed up for one year, 29(96.7%) went into remission at day 30. Remission was sustained in 23(76.6%) at day 180 and 21(70%) at 1 year. There was significant decrease [P <0.001] in the dose of steroids needed to maintain remission at 180 days following rituximab (0.27±0.02mg/Kg to 0.02±0.00mg/Kg). Of the five patients with MN, four patients achieved remission by 6 months. Remission was sustained in three patients by 1 year. Of the 7 kidney transplant recipients, 2 had antibody mediated rejections though CD19 B cells were suppressed even at one year. Conclusion Low dose of 100 mg rituximab is sufficient to deplete CD19 B cells for up to 90days and is effective in inducing remission in SDNS and FRNS and MN. Targeting subsequent doses depending on CD19 B cell reconstitution may prevent relapses, limit toxicity and be cost effective.

Sign in / Sign up

Export Citation Format

Share Document